Difusion

DiFUSION Technologies, Inc. is an advanced biomaterials manufacturer located in Georgetown Texas. DiFUSION has developed multiple patent pending MITA Technologies (Metallic Ion Therapeutic Agents) for antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold construction and increased angiogenesis. Our first product CleanFUZE™* was developed as an antimicrobial load-bearing biomaterial for orthopaedic applications and has proven highly successful in animal testing. CleanFUZE™ is currently being scaled up for regulatory submission. DiFUSION is dedicated to leveraging these breakthroughs across multiple healthcare channels – initially targeting the orthopedic market to reduce the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.

The company was founded and incorporated by Derrick Johns in 2008 as DiFUSION Technologies, Inc. DiFUSION’s Scientific Advisory Board members comprise a team of recognized physicians in the fields of orthopaedics, spinal, biochemical and genetic research. The management team consists of senior-level executives possessing extensive experience in spinal product development and clinical studies. DiFUSION is funded by private investors, having raised $9.2 million since their incorporation – none of which is venture capital or bank funding. They are also able to capture additional funding from the revenue stream provided by their first commercial line, Xiphos™ Posterior Interbody System, launched in October of 2011.

Market

Surgical Site Infections (SSIs) are a common complication surgeons confront in orthopedic surgery, with an estimated 780,000 post-operative infections occurring in the United States each year. Antibiotic-resistant bacteria such as MRSA (also known as “Superbugs”) have been a growing concern with a rising incidence of both hospital and community acquired MRSA infections. Post-operative spine infections have been reported in large studies to range in incidence from 2.5% to 13%, costing the health care industry an estimated $150 million dollars a year. SSIs have been a focal point for quality improvement as part of the “pay for performance” initiative for both hospitals and physicians. There is a growing mandate in the medical and healthcare communities to develop protocols to minimize or eliminate SSIs within hospitals, such as the Ascension Heath Surgical Care Improvement Project. DiFUSION aims to play an enormous role in the efforts to eliminate SSIs and their overall damaging impact to the medical arena.

*CleanFUZE™ is not FDA approved for sale in the U.S.*